Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, Lissoni A, Losa G, Fanucchi A
Department of Obstetrics and Gynecology, University of Pisa, Italy.
Gynecol Oncol. 1996 Nov;63(2):247-53. doi: 10.1006/gyno.1996.0314.
The objective of this retrospective multicenter study was to assess the rates, times, and sites of recurrences of 26 patients with low-grade endometrial stromal sarcomas (ESS) (<10 mitoses per 10 high-power fields (HPF) and 40 patients with high-grade ESS (>10 mitoses/10 HPF). Surgery was the initial therapy for all patients. Postoperative treatment was given without well-defined protocols. The median follow-up of survivors was 92 months (range, 4-167). Low-grade ESS: Of the 20 patients with disease confined to the uterus, 5 (25.0%) developed pelvic recurrence after a median of 36 months (range, 4-108). Of the 6 patients with disease outside the uterus, only one recurred in the pelvis after 93 months. High-grade ESS: Of the 20 patients with disease confined to the uterus, 11 (55.0%) developed recurrent disease after a median of 5 months (range, 2-76). The relapse occurred in the pelvis in 3 patients, in upper abdomen in 3, in upper abdomen and extraabdominal sites in 1, and in the pelvis and upper abdomen or extraabdominal sites in 4. Of the 12 patients with extrauterine disease confined to the pelvis, 9 (75.0%) developed recurrent disease after a median of 12 months (range, 1-49). The relapse occurred in the pelvis in 3 patients, in extraabdominal sites in 3, and in the pelvis and upper abdomen or extraabdominal sites in 3. Of the 8 patients with extrauterine disease outside the pelvis, 7 died of disease and 1 is currently alive with progressive disease after 24 months. The disease-free survival was significantly better for low-grade than that for high-grade ESS (P = 0.0001). By log-rank test the disease-free survival of high-grade ESS patients was related to stage (P = 0.0466) and mitotic count (P = 0.0014), but not to age. Cox model showed that mitotic count was the only independent prognostic variable for high-grade ESS (P = 0.006). In conclusion, low-grade and high-grade ESS have a completely different biological aggressiveness and clinical behavior.
这项回顾性多中心研究的目的是评估26例低级别子宫内膜间质肉瘤(ESS)(每10个高倍视野(HPF)中核分裂象<10个)和40例高级别ESS(每10个HPF中核分裂象>10个)患者的复发率、复发时间和复发部位。手术是所有患者的初始治疗方法。术后治疗未按照明确的方案进行。幸存者的中位随访时间为92个月(范围4 - 167个月)。低级别ESS:在20例疾病局限于子宫的患者中,5例(25.0%)在中位36个月(范围4 - 108个月)后出现盆腔复发。在6例子宫外有病变的患者中,只有1例在93个月后盆腔复发。高级别ESS:在20例疾病局限于子宫的患者中,11例(55.0%)在中位5个月(范围2 - 76个月)后出现疾病复发。3例患者复发于盆腔,3例于上腹部,1例于上腹部和腹部外部位,4例于盆腔和上腹部或腹部外部位。在12例子宫外病变局限于盆腔的患者中,9例(75.0%)在中位12个月(范围1 - 49个月)后出现疾病复发。3例患者复发于盆腔,3例于腹部外部位,3例于盆腔和上腹部或腹部外部位。在8例子宫外病变位于盆腔外的患者中,7例死于疾病,1例在24个月后仍存活且疾病进展。低级别ESS的无病生存期明显优于高级别ESS(P = 0.0001)。通过对数秩检验,高级别ESS患者的无病生存期与分期(P = 0.0466)和核分裂计数(P = 0.0014)有关,但与年龄无关。Cox模型显示核分裂计数是高级别ESS唯一的独立预后变量(P = 0.006)。总之,低级别和高级别ESS具有完全不同的生物学侵袭性和临床行为。